Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Author(s):

Chandler Park, MD, MSc, FACP,Guru Sonpavde, MD

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial of enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary (GU) medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, invites guests to dive deep into pivotal trial data, treatment recommendations, and ongoing research across oncology specialties.

In part 1 of a 3-part series, Dr Park sits down with Guru Sonpavde, MD, to discuss the clinical implications of the phase 3 EV-302 trial (NCT04223856) of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in untreated advanced urothelial cancer. Dr Sonpavde is the medical director of GU Oncology, as well as the assistant director of the Clinical Research Unit and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando, Florida.

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial, considerations for community oncologists when deciding whether to prescribe enfortumab vedotin plus pembrolizumab to patients with urothelial carcinoma, their advice for monitoring and managing treatment-related toxicities with this combination, and more.